세계의 비알코올성 지방간염 치료 시장 보고서(2025년)

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025

US $ 4,490 ￦ 6,339,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,163,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,987,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

비알코올성 지방간염 치료 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 40.0%로 138억 3,000만 달러가 될 것으로 추정됩니다. 예측기간의 성장은 의약품 개발의 진보, 질병에 대한 의식의 높아짐, 유병률과 리스크 요인의 상승, 맞춤형 의료로의 이동에 기인하는 것으로 예상됩니다. 예측 기간의 주요 동향으로는 환자 중심 접근법, 기술 진보, 표적 치료, 규제 상황, 연구 진보 등이 있습니다.

인슐린 저항성 유병률 증가는 비알코올성 지방간염 치료 시장의 성장에 크게 기여하고 있습니다. 인슐린 저항성은 근육, 지방, 간세포가 인슐린에 충분히 반응하지 못하고 혈류로부터 포도당을 흡수하기 어려워지고 혈당 수치가 상승할 때 발생합니다. 이 상태는 종종 건강에 해로운 생활 습관, 설탕 과다 복용, 유전 요인 등과 관련이 있습니다. 당뇨병과 NASH 치료가 필요한 다른 간 관련 질환의 비율이 증가함에 따라 인슐린 저항성에 대한 관심이 강해지고 있습니다. 예를 들어, 2022년 1월 벨기에를 기반으로 하는 세계 당뇨병 단체인 국제 당뇨병 연합(International Diabetes Federation)의 보고에 따르면 당뇨병은 20세에서 79세의 5억 3,700만 명이 이환되고 있으며, 이는 10명 중 1명의 비율에 해당하는 것으로 기록되었습니다. 이 수치는 2030년까지 6억 4,300만 명, 2045년까지 7억 8,300만 명으로 증가할 것으로 예측됩니다. 게다가 2024년 1월 미국을 거점으로 하는 암 옹호에 중점을 둔 비영리 단체인 미국암 협회는 간암 신규 환자 수가 2023년 4만 1,210명에서 2024년 4만 1,630명으로 증가한 것으로 예측했습니다. 이와 같이, 다양한 간 질환이나 당뇨병 관련 질환에 의한 인슐린 저항성의 유병률 증가가 NASH 치료에 대한 수요를 견인하게 됩니다.

비만률 상승은 비알코올성 지방간염 치료 시장의 급성장에 크게 기여하고 있습니다. 과도한 체지방 축적을 특징으로하는 비만은 NASH의 발병률 상승을 포함한 다양한 건강 합병증과 관련이 있습니다. 세계보건기구(WHO)는 2022년 3월 전 세계 10억 명 이상이 비만의 영향을 받고 있다고 보고했습니다. 이 수치는 더욱 증가하고 2025년에는 1억 6,700만 명에 달할 것으로 예상됩니다. 이 비만 사례의 급증은 NASH의 유병률 증가와 직접 관련이 있습니다. 이 관련성은 비알코올성 지방간염 치료에 대한 세계 수요의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 비알코올성 지방간염 치료 시장의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인, 성장 억제요인)
• 최종 이용 산업의 분석
• 세계의 비알코올성 지방간염 치료 시장 : 성장률 분석
• 세계의 비알코올성 지방간염 치료 시장 실적 : 규모와 성장(2019-2024년), 10억 달러
• 세계의 비알코올성 지방간염 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년), 10억 달러
• 세계의 비알코올성 지방간염 치료 전체 시장 규모(TAM)(TAM)

제6장 시장 세분화

• 세계의 비알코올성 지방간염 치료 시장 : 약제 유형별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 비타민 E·피오글리타존
• 오칼리바
• 엘라피브라노르
• 셀론서팁 및 세니크리비록
• 오베티콜릭산
• 기타
• 세계의 비알코올성 지방간염 치료 시장 : 테스트 유형별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 혈액 검사
• 간 생검
• 화상 진단
• 세계의 비알코올성 지방간염 치료 시장 : 최종 사용자별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 병원 약국
• 소매 및 전문 약국
• 기타
• 세계의 비알코올성 지방간염 치료 시장 : 비타민 E·피오글리타존의 서브 세분화, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 비타민 E 보충제
• 피오글리타존 기반 제형
• 세계의 비알코올성 지방간염 치료 시장 : 오칼리바의 서브 세분화 : 유형별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 오칼리바(오베티콜산)를 통한 NASH 치료
• 세계의 비알코올성 지방간염 치료 시장 : 엘라피브라노르의 서브 세분화 : 유형별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 엘라피브라노르 기반 치료
• 세계의 비알코올성 지방간염 치료 시장 : 셀론서팁 및 세니크리비록의 서브 세분화 : 유형별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 셀론서팁 제제
• 세니크리빌록 제제
• 세계의 비알코올성 지방간염 치료 시장 : 오베티콜릭산 의 서브 세분화 : 유형별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 오베티콜릭산의 다른 제제
• 세계의 비알코올성 지방간염 치료 시장 : 기타 서브 세분화 : 유형별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 임상시험에 있어서의 신규 약제
• 병용 요법

제7장 지역별, 국가별 분석

• 세계의 비알코올성 지방간염 치료 시장 : 지역별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러
• 세계의 비알코올성 지방간염 치료 시장 : 국가별, 분석과 예측(2019-2034년, 2024-2029년, 2034년), 10억 달러

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 비알코올성 지방간염 치료 시장 :경쟁 구도
• 비알코올성 지방간염 치료 시장 : 기업 프로파일
  • AstraZeneca PLC 개요, 제품 및 서비스, 전략 및 재무 분석
  • Galmed Pharmaceuticals Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Genfit SA 개요, 제품 및 서비스, 전략 및 재무 분석
  • Zydus Cadila Healthcare Limited 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Gilead Sciences Inc.
• Novo Nordisk A/S
• Immuron Ltd.
• Inventiva Pharma SA
• NGM Biopharmaceuticals Inc.
• Galectin Therapeutics Inc.
• Madrigal Pharmaceuticals Corporation
• Intercept Pharmaceuticals Inc.
• Cirius Therapeutics Inc.
• Viking Therapeutics Inc.
• Eli Lilly and Company
• Terns Pharmaceuticals Inc.
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 비알코올성 지방간염 치료 시장(2029년) : 새로운 기회를 제공하는 국가
• 비알코올성 지방간염 치료 시장(2029년) : 새로운 기회를 제공하는 부문
• 비알코올성 지방간염 치료 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Non-alcoholic steatohepatitis treatment involves lifestyle modifications such as adhering to a healthy diet, regulating blood sugar levels, and achieving weight loss to address liver disease. This form of treatment targets individuals who consume minimal or no alcohol but develop fatty liver conditions. Such conditions trigger liver cell damage and inflammation, which may progress to cirrhosis.

The primary drugs used in non-alcoholic steatohepatitis treatment include vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, obeticholic acid, among others. Vitamin E and pioglitazone play pivotal roles in treating this condition. Vitamin E, a crucial fat-soluble nutrient vital for immune health, works to ameliorate NASH by reducing oxidative stress on hepatocytes, thereby mitigating liver injury and inflammation. Conversely, pioglitazone aids in enhancing insulin sensitivity and managing elevated blood sugar levels associated with type 2 diabetes. Diagnosis and assessment of treatment typically involve blood tests, liver biopsy, and imaging procedures conducted in hospital pharmacies, retail outlets, specialty pharmacies, and other medical facilities.

The non-alcoholic steatohepatitis treatment market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis treatment market statistics, including non-alcoholic steatohepatitis treatment industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis treatment market share, detailed non-alcoholic steatohepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. This non-alcoholic steatohepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $2.6 billion in 2024 to $3.6 billion in 2025 at a compound annual growth rate (CAGR) of 38.5%. The growth in the historic period can be attributed to rising prevalence of NASH, growing awareness and diagnosis, lifestyle changes and obesity epidemic, clinical research, healthcare infrastructure and access, regulatory support and clinical trials.

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $13.83 billion in 2029 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to advancements in drug development, increased disease awareness, rising prevalence and risk factor, shift towards personalized medicine. Major trends in the forecast period include patient-centric approach, technological advancements, targeted therapies, regulatory landscape, advancements in research.

The rising prevalence of insulin resistance has significantly contributed to the growth of the non-alcoholic steatohepatitis (NASH) treatment market. Insulin resistance occurs when muscle, fat, and liver cells fail to respond adequately to insulin, making it difficult for them to absorb glucose from the bloodstream, which leads to elevated blood sugar levels. This condition is often linked to an unhealthy lifestyle, excessive sugar intake, and genetic factors. The focus on insulin resistance has intensified due to the increasing rates of diabetes and other liver-related conditions that require NASH treatment. For instance, in January 2022, a report from the International Diabetes Federation, a Belgium-based global diabetes organization, indicated that diabetes currently affects 537 million people aged 20 to 79, representing one in every ten individuals. This number is projected to rise to 643 million by 2030 and 783 million by 2045. Additionally, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization focused on cancer advocacy, forecasted that the number of new liver cancer cases would increase to 41,630 in 2024, up from 41,210 in 2023. Consequently, the growing prevalence of insulin resistance due to various liver and diabetes-related diseases will drive demand for NASH treatment.

The escalating obesity rates significantly contribute to the burgeoning growth of the non-alcoholic steatohepatitis treatment market. Obesity, characterized by excessive body fat accumulation, is associated with various health complications, including the rising incidence of NASH. The World Health Organization reported over 1 billion individuals affected by obesity globally in March 2022. This figure is expected to rise, impacting 167 million people by 2025. This surge in obesity cases directly correlates with an increased prevalence of NASH. This connection drives the demand for non-alcoholic steatohepatitis treatments worldwide.

A prominent trend in the non-alcoholic steatohepatitis treatment market is the development of innovative drugs tailored to mitigate drug side effects. Pfizer Inc., in May 2022, secured FDA fast-track designation for their investigational combination therapy targeting NASH with liver fibrosis. Ervogastat (a DGAT2 inhibitor) and Clesacostat (an ACCi) have shown promise as potential NASH drugs. This FDA-backed initiative by Pfizer underscores the industry's inclination towards developing drugs addressing NASH and its associated complications.

In the realm of non-alcoholic steatohepatitis treatment, leading companies are pioneering innovative solutions like endogenous hormones to expand their market reach, drive sales, and bolster revenue. A noteworthy example is 89bio Inc's milestone achievement in September 2023, securing the U.S. FDA's Breakthrough Therapy Designation (BTD) for Pegozafermin, targeting individuals grappling with nonalcoholic steatohepatitis (NASH). Pegozafermin, an engineered glycoPEGylated analog of fibroblast growth factor 21, represents a unique approach in NASH and severe hypertriglyceridemia (SHTG) treatment. Its distinctive formulation integrates specialized glycoPEGylation technology, enabling an extended half-life without compromising potency. This innovative design significantly enhances the product's efficacy in modulating critical factors associated with lipid metabolism, NASH, and hypertriglyceridemia, exhibiting promise in reducing triglycerides, managing glycemic levels, mitigating steatosis, inflammation, and fibrosis.

In July 2022, Advanz Pharma, a pharmaceutical company headquartered in the UK, completed the acquisition of Intercept Pharmaceuticals for an undisclosed sum. This acquisition encompasses the rights outside the United States for the commercialization of Ocaliva(R) (obeticholic acid), an orphan drug utilized in treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals, Inc., based in the United States, specializes in the development of innovative synthetic bile acid analogs targeting chronic liver diseases and non-alcoholic steatohepatitis.

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Vitamin E And Pioglitazone; Ocaliva; Elafibranor; Selonsertib And cenicriviroc; Obeticholic Acid; Other Drugs Types
• 2) By Test Type: Blood Tests; Liver Biopsy; Imaging Procedures
• 3) By End User: Hospital Pharmacies; Retail And Specialty Pharmacies; Other End Users
• Subsegments:
• 1) By Vitamin E And Pioglitazone: Vitamin E Supplements; Pioglitazone-Based Formulations.
• 2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
• 3) By Elafibranor: Elafibranor-Based Treatments
• 4) By Selonsertib And Cenicriviroc: Selonsertib Formulations; Cenicriviroc Formulations
• 5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
• 6) By Other Drug Types: Novel Agents In Clinical Trials; Combination Therapies
• Companies Mentioned: AstraZeneca PLC; Galmed Pharmaceuticals Ltd.; Genfit S.A.; Zydus Cadila Healthcare Limited; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics

3. Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Alcoholic Steatohepatitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Alcoholic Steatohepatitis Treatment Market Growth Rate Analysis
• 5.4. Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Alcoholic Steatohepatitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Alcoholic Steatohepatitis Treatment Total Addressable Market (TAM)

6. Non-Alcoholic Steatohepatitis Treatment Market Segmentation

• 6.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin E And Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib And cenicriviroc
• Obeticholic Acid
• Other Drugs Types
• 6.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Liver Biopsy
• Imaging Procedures
• 6.3. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail And Specialty Pharmacies
• Other End Users
• 6.4. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Vitamin E And Pioglitazone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin E Supplements
• Pioglitazone-Based Formulations
• 6.5. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Ocaliva, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ocaliva (Obeticholic Acid) For NASH
• 6.6. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Elafibranor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Elafibranor-Based Treatments
• 6.7. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Selonsertib And Cenicriviroc, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selonsertib Formulations
• Cenicriviroc Formulations
• 6.8. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Other Formulations Of Obeticholic Acid
• 6.9. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Novel Agents In Clinical Trials
• Combination Therapies

7. Non-Alcoholic Steatohepatitis Treatment Market Regional And Country Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market

• 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Alcoholic Steatohepatitis Treatment Market

• 9.1. China Non-Alcoholic Steatohepatitis Treatment Market Overview
• 9.2. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Alcoholic Steatohepatitis Treatment Market

• 10.1. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Treatment Market

• 11.1. Japan Non-Alcoholic Steatohepatitis Treatment Market Overview
• 11.2. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Treatment Market

• 12.1. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Treatment Market

• 13.1. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Treatment Market

• 14.1. South Korea Non-Alcoholic Steatohepatitis Treatment Market Overview
• 14.2. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Treatment Market

• 15.1. Western Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• 15.2. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Treatment Market

• 16.1. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Treatment Market

• 17.1. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Alcoholic Steatohepatitis Treatment Market

• 18.1. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis Treatment Market

• 19.1. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis Treatment Market

• 20.1. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market

• 21.1. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• 21.2. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis Treatment Market

• 22.1. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Alcoholic Steatohepatitis Treatment Market

• 23.1. North America Non-Alcoholic Steatohepatitis Treatment Market Overview
• 23.2. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Alcoholic Steatohepatitis Treatment Market

• 24.1. USA Non-Alcoholic Steatohepatitis Treatment Market Overview
• 24.2. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis Treatment Market

• 25.1. Canada Non-Alcoholic Steatohepatitis Treatment Market Overview
• 25.2. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Alcoholic Steatohepatitis Treatment Market

• 26.1. South America Non-Alcoholic Steatohepatitis Treatment Market Overview
• 26.2. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis Treatment Market

• 27.1. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis Treatment Market

• 28.1. Middle East Non-Alcoholic Steatohepatitis Treatment Market Overview
• 28.2. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis Treatment Market

• 29.1. Africa Non-Alcoholic Steatohepatitis Treatment Market Overview
• 29.2. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape
• 30.2. Non-Alcoholic Steatohepatitis Treatment Market Company Profiles
  • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Galmed Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Genfit S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Zydus Cadila Healthcare Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Non-Alcoholic Steatohepatitis Treatment Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Novo Nordisk A/S
• 31.3. Immuron Ltd.
• 31.4. Inventiva Pharma SA
• 31.5. NGM Biopharmaceuticals Inc.
• 31.6. Galectin Therapeutics Inc.
• 31.7. Madrigal Pharmaceuticals Corporation
• 31.8. Intercept Pharmaceuticals Inc.
• 31.9. Cirius Therapeutics Inc.
• 31.10. Viking Therapeutics Inc.
• 31.11. Eli Lilly and Company
• 31.12. Terns Pharmaceuticals Inc.
• 31.13. Pfizer Inc.
• 31.14. Merck & Co. Inc.
• 31.15. AbbVie Inc.

32. Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis Treatment Market

35. Non-Alcoholic Steatohepatitis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Non-Alcoholic Steatohepatitis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Alcoholic Steatohepatitis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Alcoholic Steatohepatitis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료